Propanc Biopharma (PPCB) closed at $1.84 on October 30, 2026, down 12.8% from the previous close, on volume of 38,289 shares (30-day average 287,551).
Data as of October 30, 2026.
Globe Newswire (Fri, 30-Oct 8:30 AM ET)
Propanc Biopharma Appeals Nasdaq Delisting After Bid Shortfall
TipRanks (Thu, 29-Oct 5:33 PM ET)
Globe Newswire (Wed, 28-Oct 8:30 AM ET)
Globe Newswire (Mon, 26-Oct 8:30 AM ET)
Globe Newswire (Thu, 22-Oct 4:24 PM ET)
Globe Newswire (Thu, 22-Oct 8:30 AM ET)
Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
Globe Newswire (Fri, 16-Oct 8:36 AM ET)
Globe Newswire (Wed, 14-Oct 8:30 AM ET)
Globe Newswire (Wed, 7-Oct 8:30 AM ET)
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Globe Newswire (Tue, 29-Sep 8:30 AM ET)
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Propanc Biopharma trades on the NASDAQ stock market under the symbol PPCB.
As of October 30, 2026, PPCB stock price declined to $1.84 with 38,289 million shares trading.
PPCB has a beta of 2.87, meaning it tends to be more sensitive to market movements. PPCB has a correlation of 0.08 to the broad based SPY ETF.
PPCB has a market cap of $18.09 million. This is considered a Sub-Micro Cap stock.
PPCB has underperformed the market in the last year with a price return of -99.4% while the SPY ETF gained +12.3%. PPCB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -82.3% and -46.2%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
PPCB support price is $1.91 and resistance is $2.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PPCB shares will trade within this expected range on the day.
